3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Solid Tumours
5
Melanoma
5
Neurofibromatosis 1
4
Lung Neoplasms
4
Rectal Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Neurofibroma, Plexiform
2
Uveal Melanoma
1
Solid Tumors
1
Renal Insufficiency
1
Primary Myelofibrosis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Muscle Invasive Bladder Cancer
1
Locally Advanced or Metastatic Solid Tumors
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Healthy Volunteers Pharmacokinetic Study
1
Gallbladder Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Advanced Non Small Cell Lung Cancer
1
Advanced Cancer
1
Adult Solid Neoplasm
1
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Rutin
1
Gemcitabine
1
Cisplatin
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Muscle Invasive Bladder Cancer
×
AZD 6244
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled